Grifols shares surge 10.53% after-hours as company approves U.S. Biopharma IPO to raise capital for debt reduction and growth.

Grifols surged 10.53% in after-hours trading following the announcement that its board approved an initial public offering of a minority stake in its U.S. Biopharma business. The IPO aims to raise capital to reduce debt, fund strategic growth initiatives, and enhance self-sufficiency by establishing a fully integrated U.S.-based plasma-derived therapies platform. The move underscores Grifols’ strategy to strengthen its balance sheet while maintaining majority ownership of its U.S. operations, which operate 300 donation centers and major manufacturing facilities. The transaction aligns with broader efforts to expand self-sufficiency projects in key markets like Egypt and Canada, positioning Grifols as a leader in a high-growth, high-barrier plasma industry. The news reinforced investor confidence in the company’s long-term resilience and expansion potential, driving the post-market rally.